clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT01885208 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | United States of America | Q30 |
Finland | Q33 | ||
Switzerland | Q39 | ||
Netherlands | Q55 | ||
Italy | Q38 | ||
United Kingdom | Q145 | ||
Serbia | Q403 | ||
Greece | Q41 | ||
France | Q142 | ||
Argentina | Q414 | ||
Germany | Q183 | ||
Croatia | Q224 | ||
P582 | end time | 2015-07-13 | |
P131 | located in the administrative territorial entity | Puerto Rico | Q1183 |
P1050 | medical condition | diabetes | Q12206 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 813 | |
P4844 | research intervention | exenatide | Q417762 |
P6153 | research site | Novo Nordisk | Q818846 |
P1813 | short name | SUSTAIN™ 3 | |
P580 | start time | 2013-12-02 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1) |
Search more.